Edwards Lifesciences Corporation reports developments in structural heart medical technology, including surgical tissue valves, transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies. Company news commonly covers the SAPIEN TAVR platform, PASCAL transcatheter edge-to-edge repair technology, the EVOQUE transcatheter tricuspid valve replacement system, and RESILIA tissue used in surgical and transcatheter valve innovations.
Recurring updates include quarterly results, clinical-trial data presented at cardiovascular meetings, reimbursement and guideline developments affecting valve procedures, product pipeline commentary, healthcare conference appearances, access initiatives for structural heart treatment, and finance leadership or governance announcements.
Edwards Lifesciences (NYSE: EW) will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will take part in a fireside chat at 3:40 p.m. Pacific Time. A live webcast and same-day archived replay will be available on the company investor relations website.
Investors can watch the live stream at the Edwards investor relations site; replay will be posted later the same day.
Edwards Lifesciences (NYSE: EW) reported Q1 2026 sales of $1.65 billion (growth 16.7%; constant currency 12.7%) and Q1 EPS of $0.66 (adjusted EPS $0.78).
Q1 TAVR sales were $1.20 billion (14.4% growth), TMTT sales were $173 million. The company raised FY2026 sales guidance to 9%–11% and adjusted EPS range to $2.95–$3.05, completed a $500 million ASR, and held cash of ≈$2.4 billion.
Edwards Lifesciences (NYSE: EW) will announce operating results for the quarter ended March 31, 2026 after market close on Thursday, April 23, 2026, and will host an earnings conference call at 5:00 p.m. ET that day.
Dial-in numbers: (877) 704-2848 or (201) 389-0893. A live webcast and archived replay will be available in the Investor Relations section at ir.edwards.com.
Edwards Lifesciences (NYSE: EW) reported two-year TRISCEND II results presented at ACC.26 showing sustained benefits with the EVOQUE transcatheter tricuspid valve replacement system. Data showed near elimination of tricuspid regurgitation, improved health status and quality of life, no added device-related risk, and lower all-cause mortality when accounting for patient crossover.
Company noted prior 18-month ESC data and real-world evidence from >1,000 patients in the STS/ACC TVT Registry; EVOQUE is approved in the US and Europe.
Edwards Lifesciences (NYSE: EW) reaffirmed its structural heart leadership and expanded its global health initiative Every Heartbeat Matters, aiming to help 2 million more patients by the end of 2030. The program focuses on increasing diagnosis and treatment access for underserved structural heart patients, especially in low- and middle-income countries. Since 2014, the initiative and partners have impacted more than 4 million patients. The company emphasized innovation, partnerships, and the Edwards Lifesciences Foundation as vehicles to reduce financial, systemic, and geographic barriers to care.
Edwards Lifesciences (NYSE: EW) announced that CFO Scott Ullem will present at two investor conferences in March 2026: Barclays on March 10, 2026 at 10:00 a.m. ET and Leerink on March 11, 2026 at 10:00 a.m. ET.
Live webcasts of both presentations will be available on the company investor relations website, with archived recordings posted later the same day.
Edwards Lifesciences (NYSE: EW) will present at Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026. CFO Scott Ullem is scheduled to present at 10:15 a.m. ET. A live webcast and same‑day archived replay will be available on the company investor relations website.
Investors can access the webcast at the Edwards investor relations site for the presentation and later replay.
Edwards Lifesciences (NYSE: EW) reported Q4 2025 sales of $1.57B (up 13.3%) and Q4 TAVR sales of $1.16B (up 12.0%). FY2025 sales rose 11.5% with full-year TAVR sales of $4.5B. Q4 adjusted EPS was $0.58. The company raised confidence in FY2026 guidance: constant-currency revenue +8–10% and adjusted EPS $2.90–3.05, with TMTT expected to grow 35–45% to $740–780M.
Cash was ~$3.0B and total debt ~$600M. Management cited trial data, guideline updates, new approvals, and product launches as catalysts for 2026 growth.
Edwards Lifesciences (NYSE: EW) will report operating results for the quarter ended December 31, 2025 after market close on Tuesday, February 10, 2026.
The company will host a live conference call at 5:00 p.m. ET the same day. Participants can dial (877) 704-2848 or (201) 389-0893, and a live/archived webcast will be available at ir.edwards.com. Media and investor contact emails are provided for follow-up.
Edwards Lifesciences (NYSE: EW) will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast and same-day archived replay will be available on the company investor relations site.
Investors can access the webcast at http://ir.edwards.com/. Media and investor contact emails were provided for follow-up.